Who
Patrick Y. Yang
Director
Company insider
Files Form 4 as: Director, Sana Biotechnology; Director, Codexis; Director, Amyris; Director, Andeavor; Director, Celladon; EVP, Product Operations, Genentech.
In numbers
- Trades disclosed
- 135
- Buys
- 20
- Sells
- 16
- Bought
- $1.8M
- Sold
- $11.9M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 20 Sep 2006
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 6 Jun 2024filed 15 Jul 2024 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,278 at $0.00 | filing |
| 8 Mar 2024filed 11 Mar 2024 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Sold | $236K25,000 at $9.45 | filing |
| 8 Jun 2023filed 9 Jun 2023 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | CDXS CodexisChemicals | SEC FORM 4 Code A | —11,273 at $0.00 | filing |
| 6 Jun 2022filed 8 Jun 2022 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 21 Mar 2022filed 22 Mar 2022 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Bought | $204K28,000 at $7.30 | filing |
| 15 Mar 2022filed 16 Mar 2022 | CDXS CodexisChemicals | SEC FORM 4 Sold | $134K8,000 at $16.79 | filing |
| 13 Dec 2021filed 14 Dec 2021 | CDXS CodexisChemicals | SEC FORM 4 Sold | $246K7,800 at $31.59 | filing |
| 13 Dec 2021filed 14 Dec 2021 | CDXS CodexisChemicals | SEC FORM 4 Sold | $6,428200 at $32.14 | filing |
| 16 Jun 2021filed 17 Jun 2021 | CDXS CodexisChemicals | SEC FORM 4 Sold | $406K20,000 at $20.31 | filing |
| 15 Jun 2021filed 17 Jun 2021 | CDXS CodexisChemicals | SEC FORM 4 Code A | —4,796 at $0.00 | filing |
| 6 Apr 2021filed 7 Apr 2021 | CDXS CodexisChemicals | SEC FORM 4 Sold | $252K10,000 at $25.15 | filing |
| 5 Apr 2021filed 7 Apr 2021 | CDXS CodexisChemicals | SEC FORM 4 Sold | $243K10,000 at $24.27 | filing |
| 3 Feb 2021filed 18 Feb 2021 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,591 at $0.00 | filing |
| 3 Feb 2021filed 5 Feb 2021 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 5 Aug 2020filed 7 Aug 2020 | Amyrisoption or derivative | SEC FORM 4 Code A | —3,466 at $0.00 | filing |
News
Codexis (NASDAQ:CDXS) and Revvity (NYSE:RVTY) Head-To-Head ComparisonCDXS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Patrick Y. Yang; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.